James Hardie Industries (JHX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
10 Aug, 2026Executive summary
Annual Meeting scheduled for 20 August 2026 (US) and 21 August 2026 (Australia) with key proposals on executive and non-executive remuneration.
Board engaged extensively with shareholders and proxy advisors after 2025 AGM to address concerns and redesign compensation structures.
Board encourages shareholders to vote in favor of all resolutions, emphasizing alignment with shareholder interests and market practices.
Voting matters and shareholder proposals
Proposal 4: CEO's Equity Grant revised to address prior shareholder feedback, with changes to LTI structure and performance alignment.
Proposal 6: Increase to Non-Executive Director (NED) Fee Pool, reflecting updated benchmarking and tax equalization needs.
ISS and ACSI proxy advisors recommended voting against Proposals 4 and 6, but Board urges support based on implemented improvements.
Board of directors and corporate governance
Board composition maintained at 9-10 NEDs to support skills rebuilding and succession planning.
Board actively seeks to enhance capability and diversity through new appointments.
Directors' duties have expanded due to company growth, regulatory complexity, and NYSE listing.
Latest events from James Hardie Industries
- Redesigned CEO equity grant and improved compensation structure headline annual meeting proposals.JHX
Proxy filing - Net sales and adjusted EBITDA exceeded guidance, driving a raised FY27 outlook and strong cash flow.JHX
Q1 2027 - Shareholders will vote on board, pay, auditor, and governance changes after a year of major transformation.JHX
Proxy filing - Director elections, say-on-pay, auditor ratification, and governance amendments up for vote.JHX
Proxy filing - Major acquisition, board refresh, and executive pay overhaul highlight FY26 governance and strategy.JHX
Proxy filing - AZEK acquisition and synergy gains drove strong sales and EBITDA growth, with FY27 targets raised.JHX
Q4 2026 - Net sales up 30% to $1.24B, with higher EBITDA and raised FY26 guidance amid synergy progress.JHX
Q3 2026 - Q2 FY26 sales jumped 34% on AZEK deal; margins fell, but FY26 outlook and synergies improved.JHX
Q2 2026 - Record Q1 EBITDA and 4% sales growth achieved; FY25 guidance reaffirmed amid market headwinds.JHX
Q1 2025